CeGaT, a leading laboratory provider of molecular diagnostic panel tests, has announced an agreement with N-of-One Inc, a leader in clinical interpretation for precision medicine in oncology, based in Lexington, Mass. Under the agreement, N-of-One will provide clinical interpretation for CeGaT’s next-generation sequencing (NGS) tests performed for cancer patients. Financial terms of the agreement were not disclosed.

S Biskup

Saskia Biskup, MD, PhD

CeGaT has developed a next-generation sequencing panel to simultaneously analyze more than 550 cancer-relevant genes in a tumor sample. Knowledge about the relevant mutations in a tumor helps clinicians select the most effective therapeutic strategies. CeGaT is partnering with N-of-One to provide high quality, up-to-date interpretation of mutations with very rapid turnaround times.

N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge related to the mutation profile of a tumor identified by sequencing. In turn, the firm’s interpretation links clinical knowledge to relevant therapeutic strategies, in some cases including clinical trials.

“CeGaT offers a new tool for tumor diagnostics that helps oncologists decide on the most effective therapeutic options for a patient,” said Saskia Biskup, MD, PhD, CeGaT co-founder and managing director. “N-of-One will provide the fast, scalable, and high-quality interpretation of variants needed to meet demand.”

“CeGaT’s industry-leading molecular diagnostics solutions, coupled with N-of-One’s deep expertise in clinical interpretation in oncology, will enable broader patient access to personalized medicine for cancer patients in a cost-effective manner.” said Chris Cournoyer, CEO of N-of-One.

CeGaT recently established a US-based subsidiary in partnership with B. Braun Medical. The company, B. Braun CeGaT LLC, is based in Bethlehem, Pa, and will offer the full range of CeGaT’s diagnostic testing menu to the US market.